Literature DB >> 2028945

Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients.

R Moreno-Otero1, C García-Monzón, A García-Sánchez, L García Buey, J M Pajares, A M Di Bisceglie.   

Abstract

The rate of HBeAg clearance and the outcome were analyzed in 46 patients with asymptomatic chronic hepatitis B virus (HBV) infection whose condition was followed for 1-4 yr (mean 2.4). Mean age was 32.5 yr (range 10-68), and 28 (61%) were males. All had chronic hepatitis, on biopsy, and were positive for HBcAg on hepatocytes. Alcoholics, homosexuals, drug abusers, immunocompromised patients, and those with advanced liver disease were excluded. During the follow-up, 25 patients (54%) cleared HBeAg and became seronegative for HBV-DNAp. The estimated annual rate of seroconversion was 26%. One patient cleared HBsAg. After seroconversion, 18 patients had no evidence of ongoing liver disease, proved by biopsy in eight and by clinical follow-up in 10 that refused biopsy. A second liver biopsy was available in 15 patients, and HBcAg was negative in all; histology was normal in eight, unchanged in one, and compatible with cirrhosis in six. All six had clinical and/or biochemical evidence of advanced liver disease. These were significantly older at the start of the study, and had chronic active hepatitis with bridging necrosis on initial biopsy. Early identification of patients with silent chronic HBV infection and high levels of viral replication for antiviral therapy could prevent transmission of the infection and stop progression to liver cirrhosis and hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2028945

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

Review 1.  Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Authors:  Shanhinul Alam; Nooruddin Ahmad; Golam Mustafa; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

3.  Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S.

Authors:  M'Kiaira K Miriti; Kaafee Billah; Cindy Weinbaum; Julie Subiadur; Richard Zimmerman; Paula Murray; Robert Gunn; Joanna Buffington
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792

Review 4.  Hepatitis B virus: inactive carriers.

Authors:  Sanjeev Kumar Sharma; Nitin Saini; Yogesh Chwla
Journal:  Virol J       Date:  2005-09-28       Impact factor: 4.099

5.  Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up.

Authors:  Shahnaz Sali; Seyed Moayed Alavian; Graham R Foster; Hossein Keyvani; Leila Mehrnoosh; Navid Mohammadi
Journal:  Hepat Mon       Date:  2013-07-08       Impact factor: 0.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.